medigle
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
medigle - overview
Established
2022
Location
Osaka-shi, Osaka, Japan
Primary Industry
Healthcare IT
About
Based in Osaka, Japan, and founded in 2022, medigle operates as a software company that provides a regional medical cooperation platform and digital solutions for hospitals and medical institutions to aid in patient management and referrals. In January 2023, medigle raised JPY 50 million in seed funding from ANOBAKA and East Ventures. medigle offers a cloud system for regional medical cooperation called as MediGuru that can help patients to see primary care doctors, obtain referrals, and promote reverse referrals. The company also provides hospitals all over the country, regardless of the management body as private or public, and the scale of the hospital by creating an environment where patients themselves can find their own "family doctor".
The company plans to use the January 2023 funds raised to invest in business and service offerings expansion.
Current Investors
East Ventures, ANOBAKA, Global Brain
Primary Industry
Healthcare IT
Sub Industries
eMarketing/Digital Marketing, Education & Training Services, Healthcare IT, Web Development, Customer Relationship Management, Analytics & Performance Software
Website
www.medigle.jp/
Verticals
AdTech, Cloud Computing, HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.